Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 8Terminated 3Recruiting 3Suspended 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 1

Interventions

Cisplatin 4Docetaxel 3pembrolizumab 2Nivolumab 2Etoposide 2Carboplatin 2osimertinib 1icotinib 1famitinib 1durvalumab 1decitabine and cedazuridine drug combination 1dabrafenib 1cemiplimab 1alirocumab 1aldesleukin 1Surgical Procedures, Operative 1Specimen Handling 1Radiotherapy 1Radiosurgery 1Radionuclide Imaging 1Radiation 1Prednisone 1Positron-Emission Tomography 1Platinum 1Pemetrexed 1Panitumumab 1Paclitaxel 1Monatide (IMS 3015) 1Methods 1Magnetic Resonance Spectroscopy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Suspended × Panitumumab × Thoracic × Clear all
NCT01088620 2013-03-14

Panitumumab Plus Pemetrexed and Cisplatin (PemCisP) Versus PemCis in the First-line Treatment of Patients With Non-small Cell Lung Cancer

WiSP Wissenschaftlicher Service Pharma GmbH

Phase 2 Suspended
134 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡